相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial
Loren Laine et al.
GASTROENTEROLOGY (2023)
A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race, Disease Status, and Other Covariates on Exposure
Carmelo Scarpignato et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2022)
Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects
Loren Laine et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2022)
The Effect of Food on the Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan
Darcy J. Mulford et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2022)
Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function
Mijeong Son et al.
FRONTIERS IN IMMUNOLOGY (2022)
Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial
William D. Chey et al.
GASTROENTEROLOGY (2022)
The appropriate cutoff gastric pH value forHelicobacter pylorieradication with bismuth-based quadruple therapy
Haoran Ke et al.
HELICOBACTER (2021)
Vonoprazan shows efficacy similar to that of proton pump inhibitors with respect to symptomatic, endoscopic, and histological responses in patients with eosinophilic esophagitis
Takuya Kuzumoto et al.
ESOPHAGUS (2021)
Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis
Theodore Rokkas et al.
GASTROENTEROLOGY (2021)
AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review
Shailja C. Shah et al.
GASTROENTEROLOGY (2021)
Review article: potassium-competitive acid blockers for the treatment of acid-related disorders
Yousef Abdel-Aziz et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)
Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis
Yinglian Xiao et al.
GUT (2020)
Randomised trial of acid inhibition by vonoprazan 10/20 mg once daily vs rabeprazole 10/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study)
Toshihisa Takeuchi et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Pharmacologic treatment of GERD: Where we are now, and where are we going?
Carmelo Scarpignato et al.
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES (2020)
Eosinophilic esophagitis in Japan: Focus on response to acid suppressive therapy
Norihisa Ishimura et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2018)
Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole
Kiyoshi Ashida et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype
T. Kagami et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression
Carmelo Scarpignato et al.
BMC MEDICINE (2016)
Vonoprazan: MarKed Competition for PPIs?
David R. Scott et al.
DIGESTIVE DISEASES AND SCIENCES (2016)
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study
Kazunari Murakami et al.
GUT (2016)
Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects
H. Jenkins et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Editorial: towards extended acid suppression - the search continues
C. Scarpignato et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Acid-inhibitory effects of vonoprazan 20mg compared with esomeprazole 20mg or rabeprazole 10mg in healthy adult male subjects - a randomised open-label cross-over study
Y. Sakurai et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Unmet Needs in the Treatment of Gastroesophageal Reflux Disease
Ram Dickman et al.
JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY (2015)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects
Yuuichi Sakurai et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2015)
The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin
E. A. Marcus et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy
Mitsushige Sugimoto et al.
HELICOBACTER (2007)
Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis
P. O. Katz et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Circadian pattern of intragastric acidity in patients with non-erosive reflux disease (NERD)
P Zentilin et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Detection of Helicobacter pylori antigen in stool by enzyme immunoassay
PS Kim et al.
YONSEI MEDICAL JOURNAL (2002)